IART Integra LifeSciences Holdings Corporation

Integra LifeSciences to Host Fourth Quarter and Full-Year 2019 Financial Results Conference Call on February 19, 2020

Integra LifeSciences to Host Fourth Quarter and Full-Year 2019 Financial Results Conference Call on February 19, 2020

PRINCETON, N.J., Feb. 05, 2020 (GLOBE NEWSWIRE) -- (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full-year 2019 financial results on Wednesday, February 19, 2020 prior to market open.  In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.

The live call is accessible by dialing (800) 367-2403 and using the passcode 7727863.  A simultaneous webcast of the call will be available via the Company’s website at .

A webcast replay of the call can be accessed through the homepage of Integra's website at .  A replay of the call will be available until February 24, 2020 by dialing (888) 203-1112 and using the passcode 7727863.

About Integra LifeSciences

Integra LifeSciences is a global leader in regenerative technologies, neurosurgical and extremity orthopedic solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra offers a comprehensive portfolio of high quality, leadership brands that include AmnioExcel®, Bactiseal®, Cadence®, Certas™, Codman®, CUSA®, DuraGen®, DuraSeal®, ICP Express®, Integra®, MediHoney®, MicroFrance®, PriMatrix®, Salto Talaris®, SurgiMend®, TCC-EZ®, Titan™ and VersaTru™.  For the latest news and information about Integra and its brands, please visit .

Investor Relations:

Sravan Emany

Senior Vice President, Strategy, Treasury & Investor Relations

(609) 936-2488

Michael Beaulieu

Director, Investor Relations

(609) 750-2827

 

Media Contact:

Laurene Isip

Senior Director, Global Corporate Communications

(609) 750-7984

EN
05/02/2020

Underlying

IARTIntegra LifeSciences Holdings Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Integra LifeSciences Holdings Corporation

 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences Leadership to Present at the Citi 2025 Global Hea...

Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer Mojdeh Poul and chief financial officer Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025 at 10:30 a.m ET A live webcast of the presentation will be available on the Integra LifeSciences investor relations website under . About Integra LifeSciencesAt Integra LifeSc...

December 1, 2025 1 EN
 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences Welcomes Policy Advancements Supporting Medicare ...

Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access Company to advance care through broader access to breadth of skin substitutes across four unique technology platforms PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, commends the Centers for Medicare & Medicaid Services (CMS) on its Calendar Year 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules. All Integra dermal regenerative templates, decellularized dermal scaffolds and amniotic tissue membranes, ...

November 25, 2025 1 EN
 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA...

Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearance for use of its for cardiac surgeries. The recent clearance for specific cardiac indications encompasses the debridement of unwanted tissue in cardiac surgeries, including valve replacement and repair. In addition to cardiac surgery, the CUSA Clarity Ultrasonic Surgical Aspirator System is ind...

November 11, 2025 1 EN
 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences Reports Third Quarter 2025 Financial Results

Integra LifeSciences Reports Third Quarter 2025 Financial Results PRINCETON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the third quarter ending September 30, 2025. Third Quarter 2025 Highlights Third quarter revenues of $402.1 million increased 5.6% on a reported basis and 5.0% on an organic basis compared to the prior year. Third quarter GAAP earnings per diluted share of $(0.07), compared to $(0.14) in the prior year. Adjusted earnings per diluted s...

October 30, 2025 1 EN
 PRESS RELEASE
Free
IART Integra LifeSci...

Integra LifeSciences to Host Third Quarter 2025 Financial Results Conf...

Integra LifeSciences to Host Third Quarter 2025 Financial Results Conference Call on October 30, 2025 PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: IART), a leading global medical technology company, will release third quarter 2025 financial results on Thursday, October 30, 2025, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company’s website at . For those planning to participate on the call, register  to receive dia...

October 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch